Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AACR 2024 : Cancer vaccines get reintroduction with pathway

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 12, 2024 10:54am

66 Views

Post# 35985633

RE:RE:AACR 2024 : Cancer vaccines get reintroduction with pathway

April 12, 2024 - " ..... a few key themes became apparent at the American Association for Cancer Research’s annual meeting [AACR24].

First and foremost, the programs presented are tackling difficult cancers with a high unmet need and a dire prognosis. Some of the presentations last weekend involved drug candidates targeting pancreatic cancer, for example. In 2023, the five-year survival rate for pancreatic cancer was just 12%, according to the American Cancer Society.

Two presentations—one on Bristol Myers Squibb’s blockbuster immunotherapy Opdivo, the other on a messenger RNA vaccine in development by BioNTech and Genentech—showed promising signals. Opdivo’s trial, the first reported of a PD1 inhibitor in neoadjuvant pancreatic cancer, indicated that the drug may improve outcomes, while BioNTech and Genentech’s vaccine continued to show potential in a particularly difficult-to-treat form of the disease.

This announcement also dovetailed with another prominent theme at AACR: the resurgence of cancer vaccines, which are also making inroads in advanced liver cancer, head and neck cancer, non-small cell lung cancer and glioblastoma. ... "

https://www.biospace.com/article/vaccines-next-gen-approaches-target-the-toughest-cancers-aacr/

<< Previous

Bullboard Posts

Next >>

One of the strongest contenders to lead Canada’s cannabis market